TNF and Autoimmunity: Experimental and clinical studies have demonstrated reductions in systemic inflammatory markers such as C-reactive protein, IL-6, and tumor necrosis factor (TNF)-α [9,25]. GLP-1 signaling has been shown to inhibit activation of the NLRP3 inflammasome, a key driver of innate immune-mediated inflammation, and to enhance Treg activity, suggesting a broader role in restoring immune tolerance [26,27]. These pathways position GLP-1RAs as potential modulators of autoimmunity by attenuating chronic low-grade inflammation and shifting immune balance toward regulation.